Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures

Executive Summary

Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders

You may also be interested in...



Ramucirumab Becomes First Lilly ImClone Compound To Enjoy Phase III Success

The VEGF2-inhibitor demonstrated an overall survival benefit and prolonged progression-free survival in second-line gastric cancer, Lilly said. The big pharma acquired ramucirumab through its $6.5 billion purchase of ImClone Systems in 2008.

Icahn Is Forest’s Latest Wolf At The Door

Specialty pharma Forest Pharmaceuticals Inc. has already spent months fending off doubts about the future of its pipeline as well as a potential federal ban prohibiting its long-time CEO from negotiating federal contracts. Now, the company has a new wolf at the door: dissident investor Carl Icahn.

Icahn Is Forest’s Latest Wolf At The Door

Specialty pharma Forest Pharmaceuticals Inc. has already spent months fending off doubts about the future of its pipeline as well as a potential federal ban prohibiting its long-time CEO from negotiating federal contracts. Now, the company has a new wolf at the door: dissident investor Carl Icahn.

Related Content

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel